GMEDGlobus Medical, Inc.
$74.65+34% 1Y
$74.65
$55.1052 weeks$96.82
The financials
Globus Medical, Inc. by the numbers
Globus Medical, Inc. (GMED) reported revenue of $790M in Q2 2026 (quarter ended Jun 30, 2026), up 5.9% from the same quarter a year earlier. That came with a gross margin of 69% and net income of $152M (19% of revenue). For the full year FY2025, revenue was $2.94B (+17% year on year) and net income $538M. Its largest product in Q2 2026 was Musculoskeletal Solutions at $764M, 97% of the disclosed total, well ahead of Enabling Technologies at 3.3%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $790M | $745M | +5.9% |
| Gross profit | $548M | $497M | +10% |
| Operating income | $182M | $76M | +140% |
| Net income | $152M | $203M | −25% |
| Diluted EPS | $1.10 | $1.49 | −26% |
| Product | Revenue | Share |
|---|---|---|
| Musculoskeletal Solutions | $764M | 97% |
| Enabling Technologies | $26M | 3.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $789.6M (+3.9%)
Segment Latestquarter on quarteryear on year
- Musculoskeletal Solutions$763.5M$763.5Mquarter on quarter +4.2%year on year +7.5%+4.2%+7.5%
- Enabling Technologies$26.1M$26.1Mquarter on quarter -3.0%year on year -26%-3.0%-26%
On our screens:Cheap stocks by free cash flow yield